Peptide profile
Tesamorelin
Growth hormone-releasing hormone receptor agonist
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
Egrifta has a specific FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. This does not establish general anti-aging or weight-management use.
View the supporting source- Research area
- Endocrine
- Biological target or mechanism
- Growth hormone-releasing hormone receptor agonist
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
